amprenavir has been researched along with HIV Coinfection in 212 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 60 (28.30) | 18.2507 |
| 2000's | 134 (63.21) | 29.6817 |
| 2010's | 17 (8.02) | 24.3611 |
| 2020's | 1 (0.47) | 2.80 |
| Authors | Studies |
|---|---|
| Dekhtyar, T; Kempf, DJ; Lu, L; Mo, H; Molla, A; Parkin, N; Stewart, KD | 1 |
| Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Barrail-Tran, A; Chêne, G; Clavel, F; Dam, E; Girard, PM; Le Tiec, C; Morand-Joubert, L; Poizat, G; Raguin, G; Taburet, AM | 1 |
| Ghosh, AK | 1 |
| Hu, Y; Huang, N; Li, S; Xing, W; Yan, J; Yang, LM; Zheng, YT | 1 |
| Deepa, P; Thirumeignanam, D | 1 |
| Commenges, D; Drylewicz, J; Guedj, J; Prague, M; Thiébaut, R | 1 |
| Barbour, AM; Gibiansky, L; Wire, MB | 1 |
| Duan, R; Lazim, R; Zhang, D | 1 |
| Aweeka, F; Collier, AC; Dumond, JB; Kashuba, AD; Mollan, K; Rigdon, J; Tierney, C | 1 |
| Raines, RT; Windsor, IW | 1 |
| Ganapathi, U; Gunaseelan, S; Myers, DR; Nelson, AG; Palombo, MS; Samizadeh, M; Singh, Y; Sinko, PJ; Szekely, Z; Zhang, X | 1 |
| Feicke, A; Oertle, D; Rentsch, KM; Strebel, RT | 1 |
| Hidalgo Tenorio, C; Pasquau Liaño, J | 1 |
| Chen, J; Chen, L; Gurley, E; Hylemon, PB; Pandak, WM; Sanyal, AJ; Studer, E; Sun, L; Wang, G; Wang, JY; Wang, X; Wu, X; Zha, W; Zhang, L; Zhou, H | 1 |
| Andrews, M; Condoluci, DV; Luber, AD; Olson, K; Pakes, GE; Pappa, KA; Peloquin, CA; Slowinski, PD | 1 |
| Blanco, J; Bofill, M; Cabrera, C; Clotet, B; Cunyat, F; Marfil, S; Puig, T; Ruiz, L | 1 |
| Boccara, F; Costagliola, D; Cotte, L; Gilquin, J; Lang, S; Mary-Krause, M; Partisani, M; Simon, A | 1 |
| Agniswamy, J; Amano, M; Aoki, M; Baldridge, A; Ghosh, AK; Miguel, SG; Mitsuya, H; Rao, KV; Wang, YF; Weber, IT; Xu, CX | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Borkowsky, W; DiMeglio, LA; Geffner, ME; Hazra, R; Jacobson, DL; Miller, TL; Patel, K; Silio, M; Van Dyke, RB; Worrell, C | 1 |
| Best, BM; Capparelli, E; Clifford, DB; Collier, AC; Croteau, D; Ellis, RJ; Gelman, BB; Grant, I; Letendre, S; Marra, CM; McArthur, J; McCutchan, JA; Morgello, S; Rossi, SS; Simpson, DM; Way, L | 1 |
| Kar, P; Knecht, V | 1 |
| Cau, P; Cremer, J; Dellamonica, P; Faucher, O; Kaspi, E; Lacarelle, B; Lévy, N; Micallef, J; Nicolino-Brunet, C; Perrin, S; Poizot-Martin, I; Reynes, J; Robaglia-Schlupp, A; Roll, P; Solas, C; Stretti, C; Tamalet, C; Tamalet, CN | 1 |
| Acosta, EP; Eron, JJ; Fiscus, SA; Gerber, JG; Gulick, RM; Murphy, RL; Pereira, AS; Smeaton, LM; Snyder, S; Tidwell, RR | 1 |
| Buchanan, TA; Dubé, MP; Edmondson-Melançon, H; Goodwin, D; Johnson, D; Martinez, C; Qian, D; Sattler, FR; Williams, V | 1 |
| Gamarnik, A; Parkin, N; Resch, W; Swanstrom, R; Ziermann, R | 1 |
| Chaudry, NI; Eron, JJ; Fiscus, SA; Kashuba, AD; Naderer, OJ; Pereira, AS; Wire, MB | 1 |
| Bates, M; Chappey, C; Hellmann, NS; Maroldo, L; Parkin, N; Petropoulos, CJ | 1 |
| Fusco, G; Liao, Q; Paulsen, D; Ross, L; Shaefer, M; St Clair, M | 1 |
| Fenton, M; Hall, M; Tong, C | 1 |
| Gaylord, G | 1 |
| Bidault, R; Bollens, D; Choudet, N; Demarles, D; Gillotin, C; Goujard, C; Meynard, JL; Rousseau, C; Taburet, AM; Vincent, I | 1 |
| Ait Mohand, H; Bonmarchand, M; Bossi, P; Bricaire, F; Cacace, R; Calvez, V; Costagliola, D; Delaugerre, C; Katlama, C; Ktorza, N; Lamotte, C; Marcelin, AG; Peytavin, G; Simon, A; Wirden, M | 1 |
| Bogner, JR; Eberle, J; Goebel, FD; Troendle, U | 1 |
| Chappey, C; Parkin, NT; Petropoulos, CJ | 1 |
| Zolopa, AR | 1 |
| Ait-Khaled, M; Falloon, J; Griffin, P; Rakik, A; Richards, N; Stone, C; Thomas, D; Tisdale, M | 1 |
| Gathe, JC; Griffith, S; Hernandez, JE; Lancaster, CT; Liao, Q; Nadler, JP; Pappa, KA; Pollard, RB; Richmond, GJ | 1 |
| Bates, M; Hellmann, N; Huang, W; Petropoulos, C; Wrin, T | 1 |
| Bassetti, D; Bassetti, M; Ciravegna, BW; Di Biagio, A; Ferrazin, A; Rosso, R | 1 |
| Elston, R; Paulsen, D; Ross, L; Snowden, W; Tisdale, M | 1 |
| Becker, S; Carlson, M; DeJesus, E; Delehanty, J; DeMasi, R; Haas, FF; Haubrich, R; Henry, D; Lalezari, JP; Northfelt, DW; Powderly, W; Richmond, G; Riddler, S; Salgo, M; Sista, PR; Thompson, M; Valentine, F; Wolfe, P; Wright, D | 1 |
| Cane, PA; de Ruiter, A; Easterbrook, PJ; Fisher, M; Leen, C; Li, X; Murphy, M; Pillay, D; Sabin, CA; Vlahakis, E; Wilkins, E | 1 |
| Carosi, G; Donati, E; Lo Caputo, S; Mazzotta, F; Moretti, F; Patroni, A; Quiros-Roldan, E; Scudeller, L; Torti, C; Vivarelli, A | 1 |
| Aquaro, S; Caliò, R; Di Santo, F; Francesconi, M; Guenci, T; Perno, CF | 1 |
| Arasteh, K; Eron, J; Millard, J; Naderer, OJ; Pollard, RB; Raffi, F; Stellbrink, HJ; Teofilo, E; Wire, MB; Wood, R; Yeo, J | 1 |
| Bulgheroni, E; Chou, TC; Citterio, P; Croce, F; Galli, M; Lo Cicero, M; Rusconi, S; Soster, F; Viganò, O | 1 |
| de Mendoza, C; González de Requena, D; González-Lahoz, J; Martin-Carbonero, L; Soriano, V; Valer, L | 1 |
| Barrail, A; Chêne, G; Clavel, F; Droz, C; Girard, PM; Le Tiec, C; Morand-Joubert, L; Raguin, G; Taburet, AM; Vincent, I | 1 |
| Chou, S; Marousek, GI; Murphy, MD | 1 |
| Boeri, E; Castagna, A; Danise, A; Gianotti, N; Hasson, H; Lazzarin, A; Nozza, S; Seminari, E | 1 |
| Baldini, F; Cauda, R; Cingolani, A; De Luca, A; Di Giambenedetto, S; Hoetelmans, RM | 1 |
| Brun-Vezinet, F; Clavel, F; Collin, G; Costagliola, D; Dalban, C; Descamps, D; Girard, PM; Lastere, S | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Belohradsky, BH; Engelhorn, C; Hoffmann, F; Kruse, G; Kurowski, M; Notheis, G; Stocker, H; Wintergerst, U | 1 |
| Corbett, AH; Eron, JJ; Fiscus, SA; Kashuba, AD; Rezk, NL | 1 |
| Boulmé, R; Clevenbergh, P; Dellamonica, P; Kirstetter, M | 1 |
| Cattelan, AM; Clumeck, N; Katlama, C; Marquez, M; Pedro, Rde J; Pulido, F; Thomas, R; Tymkewycz, P; Zhu, C | 1 |
| Affolabi, D; Bossi, P; Bricaire, F; Calvez, V; Costagliola, D; Delaugerre, C; Katlama, C; Ktorza, N; Lamotte, C; Marcelin, AG; Mohand, HA; Peytavin, G; Voujon, D; Wirden, M | 1 |
| Angarano, G; Carosi, G; Lo Caputo, S; Mazzotta, F; Monno, L; Patroni, A; Quiros-Roldan, E; Saracino, A; Tinelli, C; Tirelli, V; Torti, C | 1 |
| Chappuy, H; Dimet, J; Firtion, G; Fouché, M; Mandelbrot, L; Pons, G; Rey, E; Tréluyer, JM | 1 |
| Arasteh, K; Eron, J; Livrozet, JM; Millard, J; Naderer, OJ; Teofilo, E; Trepo, C; Wire, MB; Wood, R; Yeo, J | 1 |
| Brill, M; Campo, R; Chu, HM; Garg, V; Jayaweera, DT; Kolber, MA; Rodriguez, A; Tanner, T | 1 |
| Buchanan, TA; Considine, RV; Deeg, MA; Degawa-Yamauchi, M; Dubé, MP; Edmondson-Melançon, H; Hernandez, J; Sattler, FR; Shankar, S; Young, EM | 1 |
| Chêne, G; Clavel, F; Droz, C; Girard, PM; Le Tiec, C; Morand-Joubert, L; Raguin, G; Taburet, AM | 1 |
| Bigelow, GE; Christopher, J; Fuchs, EJ; Hendrix, CW; Lou, Y; Martinez, E; Snidow, JW; Wakeford, J; Wire, MB | 1 |
| Blanche, S; Johnson, M; Lou, Y; Randall, S; Stein, DS | 1 |
| Chadwick, EG; Homans, JD; Kovacs, A; Lou, Y; Symonds, WT; Yogev, R | 1 |
| Acosta, EP; Collier, AC; Downey, GF; Eshleman, SH; Kashuba, AD; Klingman, K; Mellors, JW; Scott, TR; Tierney, C; Vergis, EN | 1 |
| Arvieux, C; Tribut, O | 1 |
| Jenwitheesuk, E; Samudrala, R | 1 |
| Jaillon, P; Poirier, JM; Robidou, P | 1 |
| Brown, AJ; Clotet, B; Frost, SD; Martinez-Picado, J; Parkin, NT; Petropoulos, CJ; Ruiz, L; Wrin, T | 1 |
| Arnedo, M; Biglia, MA; Blanco, JL; García, F; Gatell, JM; Laguno, M; Larrousse, M; Leon, A; Lonca, M; Mallolas, J; Martínez, E; Milinkovic, A; Miró, JM; Pumarola, T | 1 |
| Ieki, R; Iguchi, M; Kato, T; Okamura, T; Ota, T; Saito, E; Shibuya, M; Yuasa, K | 1 |
| Castagna, A; Cusato, M; Fusetti, G; Galli, A; Gianotti, N; Guffanti, M; Lazzarin, A; Regazzi, M; Seminari, E; Villani, P | 1 |
| Elston, R; Kleinkauf, N; Schürmann, D; Suttorp, N; Wünsche, T; Xu, F | 1 |
| Bhatti, L; Farthing, C; Khanlou, H | 1 |
| Shelton, MJ; Studenberg, S; Wire, MB | 1 |
| Bacheler, L; Corral, A; de Mendoza, C; Pattery, T; Soriano, V; Valer, L | 1 |
| Huynh, P; Kohli-Pamnani, A; Lobo, F | 1 |
| Bonora, S; Cocchi, S; Codeluppi, M; Di Benedetto, F; Esposito, R; Gennari, W; Gerunda, GE; Guaraldi, G; Luzi, K; Masetti, M; Motta, A; Pecorari, M | 1 |
| Lancaster, CT; Lou, Y; Luber, AD; Pappa, KA; Ruane, PJ; Shelton, MJ; Wire, MB | 1 |
| Doron-Faigenboim, A; Pupko, T | 1 |
| Chêne, G; Clavel, F; Girard, PM; Le Tiec, C; Morand-Joubert, L; Poizat, G; Raguin, G; Taburet, AM | 1 |
| Berthé, H; de Truchis, P; Delaugerre, C; Galperine, T; Long, K; Mathez, D; Peytavin, G | 1 |
| Crane, HM; Harrington, RD; Kestenbaum, B; Kitahata, MM | 1 |
| Castagna, A; De Bona, A; Dorigatti, F; Galli, L; Gentilini, G; Gianotti, N; Lazzarin, A; Schira, G; Seminari, E; Soldarini, A; Uberti-Foppa, C | 1 |
| De Bona, A; Dorigatti, F; Galli, L; Gentilini, G; Seminari, E; Soldarini, A; Spagnuolo, V; Uberti-Foppa, C | 1 |
| Barditch-Crovo, P; Carson, KA; Flexner, C; Hendrix, CW; Khan, W; Pakes, GE; Parish, M; Parsons, T; Pham, PA; Qaqish, R; Radebaugh, C | 1 |
| de Béthune, MP; De Meyer, S; Picchio, G | 1 |
| Bruzzone, B; Cenderello, G; Dentone, C; Di Biagio, A; Ferrea, G; Icardi, G; Mularoni, A; Rosso, R; Viscoli, C | 1 |
| Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F | 1 |
| Diaz, RS; Ferreira, PA; Tenore, S | 1 |
| Delgado, O; Murillas, J; Riera, M; Ventayol, P | 1 |
| Bilello, JA; Drusano, GL | 1 |
| Blum, MR; Millard, J; Painter, G; Parry, N; Rooney, J; Sadler, BM; St Clair, MH; Tisdale, M | 1 |
| Adkins, JC; Faulds, D | 1 |
| Bart, PA; Corpataux, JM; de Boer, RJ; Fleury, S; Gallant, S; Gillet, M; Glauser, MP; Graziosi, C; Knabenhans, C; Meuwly, JY; Meylan, P; Miedema, F; Otto, SA; Pantaleo, G; Rizzardi, GP; Schnyder, P; Soudeyns, H; Spreen, W; Welbon, CC; Wolthers, KC | 1 |
| Cammack, N; Chirn, GW; Craig, C; Dissanayeke, S; Duncan, IB; Gilbert, S; Moffatt, A; Race, E; Rose, J; Sheldon, J; Whittaker, L | 1 |
| Bawdon, RE | 1 |
| Caliendo, AM; Currier, JS; D'Aquila, RT; DeGruttola, V; Eron, JJ; Frank, I; Gerber, JG; Gulick, RM; Kuritzkes, DR; Murphy, RL; Smeaton, L; Sommadossi, JP; Tung, R | 1 |
| Cassano, P; Clumeck, N; De Wit, S; Gerard, M; Hermans, P; Kabeya, K; O'Doherty, E | 1 |
| Miller, SL | 1 |
| Chittick, GE; Hanson, CD; Roskell, NS; Sadler, BM; Symonds, WT | 1 |
| Bart, PA; Corpataux, JM; Fleury, S; Knabenhans, C; Meuwly, JY; Meylan, PR; Munoz, M; Pantaleo, G; Rizzardi, P; Welbon, C; Yerly, S | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Antunes, F; Brown, DJ; Clumeck, N; Fetter, A; Haubrich, R; Kahl, L; Lang, W; Pagano, G; Richman, D; Schooley, R; Sereni, D; Stein, A; Thompson, M; van der Ende, ME | 1 |
| Gatell, J | 1 |
| Falloon, J; Kavlick, MF; LaFon, S; Lane, HC; Manion, DJ; Masur, H; Mitsuya, H; Piscitelli, S; Rogers, M; Sadler, B; Vogel, S; Yoshimura, K | 1 |
| Bart, PA; Chapuis, A; De Boer, RJ; Fox, CH; Halkic, N; Hoover, S; Lange, JM; Lazzarin, A; Miller, V; Notermans, DW; Pantaleo, G; Perrin, L; Rizzardi, GP; Staszewski, S; Tambussi, G | 1 |
| Arnold, E; Das, K; Limoli, K; Parkin, NT; Petropoulos, CJ; Ziermann, R | 1 |
| Currier, JS; D'Aquila, RT; Eron, JJ; Fiscus, SA; Gulick, RM; Lennox, JL; Murphy, RL; Rogers, MD; Smeaton, LM; Tung, R | 1 |
| Biollaz, J; Buclin, T; Decosterd, LA; Marzolini, C; Telenti, A | 1 |
| Condra, JH; Emini, EA; Petropoulos, CJ; Schleif, WA; Shivaprakash, M; Ziermann, R | 1 |
| Binley, JM; Clas, B; Hurley, A; Ketas, T; Little, S; Markowitz, M; Moore, JP; Richman, D; Schiller, D; Trkola, A | 1 |
| Belohradsky, BH; Engelhorn, C; Hoffmann, F; Kurowski, M; Notheis, G; Wintergerst, U | 1 |
| Bart, PA; Chapuis, AG; Chave, JP; Corpataux, JM; Graziosi, C; Halkic, N; Lazzarin, A; McDade, H; Meuwly, JY; Meylan, P; Munoz, M; Pantaleo, G; Perrin, L; Rizzardi, GP; Spreen, W; Tambussi, G; Yerly, S | 1 |
| Duval, X; Farinotti, R; Lamotte, C; Le Moing, V; Leport, C; Longuet, C; Peytavin, G; Vildé, JL | 1 |
| Korn, K; Moschik, B; Paatz, C; Schmidt, B; Uberla, K; Walter, H | 1 |
| Tavel, JA | 1 |
| Brothers, CH; Feinberg, J; Fischl, M; Goodgame, JC; Hardy, WD; Jablonowski, H; Morrow, P; Nacci, P; Pedneault, L; Pottage, JC; Stein, A; Vafidis, I; Yeo, J | 1 |
| Bart, PA; Chapuis, AG; Lazzarin, A; Pantaleo, G; Rizzardi, GP; Tambussi, G | 1 |
| Goa, KL; Noble, S | 1 |
| Carr, A; Cooper, DA; Cunningham, PH; Goh, LE; Grey, P; Kaufmann, GR; Smith, D; Suzuki, K; Zaunders, JJ | 1 |
| Acosta, E; Currier, JS; D'Aquila, RT; Eron, JJ; Gerber, JG; Gulick, RM; Kuritzkes, DR; Murphy, RL; Smeaton, LM; Snyder, S; Sommadossi, JP; Tung, R | 1 |
| Brothers, C; Fetter, A; Millard, J; Pagano, G; Pedneault, L; Tymkewycz, P; Yeo, J | 1 |
| Ishizawa, M; Komatsu, H | 1 |
| Garrett, L; Garris, C; Graham, N; Pedneault, L; Rogers, M; Scott, T | 1 |
| Caldwell, P; Furlan, S; Ho, D; Hurley, A; Johnson, J; Kost, RG; Markowitz, M; Smiley, L; Talal, A; Vesanen, M; Zhang, L | 1 |
| Brothers, CH; Scott, TR; Stein, AJ | 1 |
| Griswold, MP; Gunawan, S; Kahn, DG | 1 |
| Levin, J | 1 |
| Chang, HE | 1 |
| Coppedge, B | 1 |
| Baker, R; Bowers, M | 1 |
| Fakuda, D | 2 |
| Bartnof, HS | 1 |
| Gilden, D | 2 |
| Highleyman, L | 3 |
| Elwell, A | 1 |
| Prescott, LM | 1 |
| Gallant, JE | 1 |
| James, JS | 1 |
| Simmons, P | 1 |
| Fornataro, K; Jefferys, R | 1 |
| Arroyo, HT | 1 |
| Bartnoff, H; Deeks, S; Follansbee, S | 1 |
| Eron, JJ; Haubrich, R; Lang, W; Millard, J; Pagano, G; Pedneault, L; Snowden, W; Tisdale, M; Wolfram, J | 1 |
| Blanco, JL; Carné, X; Gatell, JM; López-Púa, Y; Mallolas, J; Sarasa-Nacenta, M | 1 |
| Arrizabalaga, J; Clotet, B; Martínez-Picado, J; Ruiz, L | 1 |
| Bakshi, S; Black, K; Kodoth, S; Pahwa, S; Scimeca, P | 1 |
| Antunes, F; Blake, D; Clumeck, N; Danner, SA; Haubrich, R; Millard, J; Mustafa, N; Myers, RE; Nacci, P; Schooley, RT; Sereni, D; Thompson, M; Tisdale, M; van Der Ende, ME | 1 |
| Huff, B | 1 |
| Mazzullo, JM; Piliero, PJ | 1 |
| Burger, D; Fätkenheuer, G; Kamps, R; Römer, K; Salzberger, B | 1 |
| D'Aquila, RT; Hanna, GJ; Zachary, KC | 1 |
| Pereira, A; Taylor, S | 1 |
| Gatell, JM | 1 |
| Clavel, F; Damond, F; Descamps, D; Duval, X; Lamotte, C; Leport, C; Peytavin, G; Race, E; Vilde, JL | 1 |
| Kuschak, D; Mauss, S; Schmutz, G | 1 |
| Sadler, BM; Stein, DS | 1 |
| Cohen, DM; James, CW; Matalia, MD; McNelis, KC; Szabo, S | 1 |
| Ait-Khaled, M; Brosgart, CL; Eron, JJ; Falloon, J; Feinberg, J; Flanigan, TP; Hammer, SM; Kraus, PW; Masur, H; Murphy, R; Thomas, DA; Torres, R | 1 |
| Elston, R; Harris, W; Klein, A; Maguire, M; Manohitharajah, V; May, J; Parker, H; Randall, S; Shortino, D; Snowden, W; Tisdale, M; Xu, F; Yeo, J | 1 |
| Solignac, M | 1 |
| Andersson, J; Cooper, D; Goh, LE; Hoen, B; Janossy, G; Kinloch, S; Lampe, F; Perrin, L; Tilling, R; Tsoukas, C; Zaunders, J | 1 |
| Brill, M; Farthing, C; Graham, E; Khanlou, H | 1 |
| Alexander, C; Harris, M; Montaner, JS; O'Shaughnessy, M | 1 |
| Perrin, L | 1 |
| Edno-Mcheik, L; Lagrange, F; Molimard, M; Moore, N; Péhourcq, F; Titier, K | 1 |
| Aberg, JA; Bennett, KK; Bessen, LJ; Brosgart, C; DeGruttola, V; Eron, JJ; Gulick, RM; Hammer, SM; Holohan, MK; Karol, CN; Lewis, RH; Mellors, JW; Mitsuyasu, RT; Rogers, MD; Saah, AJ; Sheiner, L; Vaida, F; Valentine, FT; Wheat, LJ | 1 |
19 review(s) available for amprenavir and HIV Coinfection
| Article | Year |
|---|---|
Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Antiviral Agents; Aspartic Acid Endopeptidases; Biological Products; Darunavir; Drug Design; Drug Discovery; Drug Resistance, Viral; Enzyme Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Molecular Mimicry; Molecular Structure; Peptides; Structure-Activity Relationship; Sulfonamides | 2009 |
[Chemical characteristics, mechanism of action and antiviral activity of darunavir].
Topics: Administration, Oral; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Darunavir; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Molecular Structure; Ritonavir; Sulfonamides | 2008 |
Practical applications of viral fitness in clinical practice.
Topics: Carbamates; Drug Resistance, Viral; Furans; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Models, Biological; Mutation; Sulfonamides; Viral Load; Virus Replication | 2003 |
Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.
Topics: Carbamates; Drug Resistance, Viral; Furans; Genetic Linkage; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Phenotype; Pyrimidinones; Sulfonamides | 2003 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Ritonavir; Sulfonamides | 2005 |
Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
Topics: Adult; Carbamates; Drug Interactions; Furans; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intestinal Absorption; Organophosphates; Prodrugs; Reverse Transcriptase Inhibitors; Sulfonamides; Tissue Distribution | 2006 |
Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".
Topics: Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; Treatment Outcome | 2008 |
Amprenavir.
Topics: Animals; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Rats; RNA, Viral; Sulfonamides | 1998 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Coming therapies: amprenavir.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides | 1999 |
Ongoing trials in HIV protease inhibitors.
Topics: Carbamates; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; United States; United States Food and Drug Administration | 2000 |
Amprenavir: a review of its clinical potential in patients with HIV infection.
Topics: Animals; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Molecular Structure; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2000 |
[Pharmacological study and clinical effect of HIV protease inhibitor amprenavir].
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Food-Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Mixed Function Oxygenases; Sulfonamides | 2001 |
[Resistance to protease inhibitors].
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac.
Topics: Adult; Carbamates; Diagnosis, Differential; Factor VIII; Furans; Hemophilia A; HIV Infections; HIV Protease Inhibitors; Humans; Intracranial Hemorrhages; Male; Sulfonamides; Tomography, X-Ray Computed | 2001 |
Penetration of HIV-1 protease inhibitors into CSF and semen.
Topics: Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Ritonavir; Saquinavir; Semen; Sulfonamides; Viral Load | 2000 |
From amprenavir to GW433908.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Furans; HIV Infections; Humans; Organophosphates; Prodrugs; Sulfonamides | 2001 |
Clinical pharmacology and pharmacokinetics of amprenavir.
Topics: Carbamates; Drug Interactions; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Sulfonamides; Tissue Distribution | 2002 |
54 trial(s) available for amprenavir and HIV Coinfection
| Article | Year |
|---|---|
Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.
Topics: Adult; Aged; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Phenotype; Prognosis; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
Topics: Adolescent; Carbamates; Child; Child, Preschool; Computer Simulation; Drug Dosage Calculations; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Models, Biological; Organophosphates; Prodrugs; Ritonavir; Sulfonamides | 2014 |
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Organophosphonates; Prodrugs; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2010 |
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study.
Topics: Aging; Atazanavir Sulfate; Carbamates; Cross-Sectional Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamin Type A; Leukocytes, Mononuclear; Longitudinal Studies; Lopinavir; Male; Nuclear Proteins; Oligopeptides; Protein Precursors; Pyridines; Ritonavir; Sulfonamides; Viral Load | 2012 |
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; Genitalia, Male; HIV Infections; HIV-1; Humans; Lamivudine; Male; RNA, Viral; Semen; Statistics, Nonparametric; Sulfonamides; Zidovudine | 2002 |
Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oxazines; Ritonavir; Sulfonamides | 2003 |
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Topics: Adult; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Predictive Value of Tests; Ritonavir; Sulfonamides; Viral Load | 2003 |
Amprenavir in pre-treated patients: virological and immunological response in a cohort of 45 patients.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load; Viremia | 2003 |
HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Oxazines; Salvage Therapy; Sulfonamides | 2003 |
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV-1; Humans; Male; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2003 |
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Enfuvirtide; Female; Furans; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Peptide Fragments; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2003 |
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.
Topics: Algorithms; Carbamates; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Phenotype; Prospective Studies; Sulfonamides; Treatment Outcome | 2003 |
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; RNA, Viral; Sulfonamides | 2004 |
Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.
Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Mutation; Patient Selection; Phenotype; Predictive Value of Tests; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load | 2004 |
Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
Topics: Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Biological Availability; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Lopinavir; Male; Maximum Tolerated Dose; Middle Aged; Probability; Pyrimidinones; Risk Assessment; Ritonavir; Salvage Therapy; Severity of Illness Index; Single-Blind Method; Statistics, Nonparametric; Sulfonamides; Survival Rate; Treatment Outcome; Viral Load | 2004 |
Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pilot Projects; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides | 2004 |
Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.
Topics: Adult; Amino Acid Motifs; Amino Acid Sequence; Carbamates; Female; Furans; gag Gene Products, Human Immunodeficiency Virus; Gene Products, gag; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Phenotype; RNA, Viral; Sequence Analysis, DNA; Sulfonamides; Viral Load | 2004 |
The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir.
Topics: Adult; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; Salvage Therapy; Saquinavir; Sulfonamides; Viral Load | 2004 |
Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease; HIV-1; Humans; Logistic Models; Male; Mutation; Prospective Studies; Salvage Therapy; Sulfonamides; Viral Load | 2004 |
A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Female; Furans; Genes, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; Sulfonamides | 2004 |
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Carbamates; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Ritonavir; Sulfonamides | 2004 |
Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy.
Topics: Adult; Biomarkers; Blood Glucose; Carbamates; Drug Therapy, Combination; Female; Fibrinolysis; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Inflammation; Insulin Resistance; Male; Plasminogen Activator Inhibitor 1; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Sulfonamides; Tissue Plasminogen Activator | 2004 |
Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
Topics: Adult; Aged; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Viral Load | 2004 |
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Male; Methadone; Opioid-Related Disorders; Reaction Time; Stereoisomerism; Sulfonamides | 2004 |
Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.
Topics: Adolescent; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Male; Sulfonamides | 2004 |
Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children.
Topics: Area Under Curve; Carbamates; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Sulfonamides; Treatment Outcome | 2005 |
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
Topics: Adult; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides; Treatment Outcome | 2005 |
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Prodrugs; Ritonavir; Sulfonamides | 2007 |
Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Multiple, Viral; Follow-Up Studies; Furans; HIV Infections; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides | 2007 |
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides | 2007 |
Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pilot Projects; Prospective Studies; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Treatment Outcome | 2008 |
In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents.
Topics: Carbamates; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine | 1996 |
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Sulfonamides; Zidovudine | 1999 |
Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Biological Availability; Carbamates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Male; Middle Aged; Sulfonamides | 1999 |
Sampling lymphoid tissue cells by ultrasound-guided fine needle aspiration of lymph nodes in HIV-infected patients. Swiss HIV Cohort Study.
Topics: Anti-HIV Agents; Biopsy, Needle; Carbamates; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dideoxynucleosides; Drug Therapy, Combination; Flow Cytometry; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Longitudinal Studies; Lymph Nodes; Lymphocyte Activation; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Ultrasonography | 1999 |
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nausea; RNA, Viral; Safety; Sulfonamides; Time Factors; Viremia; Zidovudine | 1999 |
Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.
Topics: Adult; Alkynes; Antiviral Agents; Area Under Curve; Base Sequence; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Oxazines; Phenotype; Pilot Projects; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2000 |
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).
Topics: Adult; Carbamates; Double-Blind Method; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Regression Analysis; RNA, Viral; Semen; Sulfonamides; Virus Shedding; Zidovudine | 2000 |
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
Topics: Carbamates; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Phenotype; Protein Binding; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; CD4-CD8 Ratio; Dideoxynucleosides; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lymph Nodes; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Viral Load | 2000 |
Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
Topics: Adolescent; Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Zidovudine | 2000 |
Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
Topics: Adult; Anti-HIV Agents; Antigens, Fungal; Antigens, Viral; Antiretroviral Therapy, Highly Active; Candida albicans; Carbamates; CD4 Lymphocyte Count; Chronic Disease; Cytomegalovirus; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Simplexvirus; Sulfonamides; T-Lymphocyte Subsets | 2000 |
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Male; Nevirapine; Odds Ratio; Prospective Studies; RNA, Viral; Safety; Stavudine; Sulfonamides; Time Factors; Treatment Outcome; Viral Load | 2001 |
Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection.
Topics: Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Digestive System; Drug Therapy, Combination; Exanthema; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Paresthesia; Sulfonamides | 2000 |
Safety profile and tolerability of amprenavir in patients enrolled in an early access program.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Sulfonamides | 2001 |
Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Chronic Disease; Dideoxynucleosides; Digestive System; Drug Synergism; Ethnicity; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Subsets; Male; Pregnancy; Research Design; RNA, Viral; Sulfonamides; Treatment Refusal; Zidovudine | 2001 |
Phase III results presented on amprenavir triple combination.
Topics: Anti-HIV Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Sulfonamides; Zidovudine | 1998 |
A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir.
Topics: Adult; Aged; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Treatment Outcome | 2001 |
A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maximum Tolerated Dose; Phenotype; Sulfonamides; Time Factors; Treatment Outcome | 2001 |
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Female; Furans; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Phenotype; Retrospective Studies; RNA, Viral; Safety; Sulfonamides; Treatment Failure | 2002 |
Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleos
Topics: Carbamates; Cloning, Molecular; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; Genotype; HIV Core Protein p24; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sulfonamides | 2002 |
Therapeutic vaccination in primary HIV infection, the Quest trial.
Topics: AIDS Vaccines; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Defective Viruses; Dideoxynucleosides; Furans; HIV Infections; Humans; Immunotherapy, Active; Lamivudine; Lymphocyte Count; Sulfonamides; T-Lymphocyte Subsets; Vaccination; Vaccinia virus; Viral Load; Viral Vaccines; Viremia; Zidovudine | 2002 |
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Organophosphonates; Oxazines; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Saquinavir; Sulfonamides; Treatment Failure; Viral Load | 2002 |
139 other study(ies) available for amprenavir and HIV Coinfection
| Article | Year |
|---|---|
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genes, gag; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation; Nelfinavir; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Virus Replication | 2007 |
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication | 2007 |
Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
Topics: Carbamates; Catalytic Domain; Cell Line; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Sulfonamides | 2012 |
Understanding the impact of halogen functional group (Br, Cl, F, OH) in amprenavir ligand of the HIV protease.
Topics: Amino Acids; Halogens; HIV Infections; HIV Protease; Humans; Ligands; Models, Molecular | 2023 |
NIMROD: a program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations.
Topics: Algorithms; Anti-HIV Agents; Bayes Theorem; Carbamates; Clinical Trials as Topic; Drug Monitoring; Furans; HIV Infections; Humans; Likelihood Functions; Models, Statistical; Reproducibility of Results; Software; Sulfonamides | 2013 |
Understanding the basis of I50V-induced affinity decrease in HIV-1 protease via molecular dynamics simulations using polarized force field.
Topics: Carbamates; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Dynamics Simulation; Point Mutation; Protein Binding; Sulfonamides | 2015 |
Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Sulfonamides; Viral Load | 2015 |
Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.
Topics: Carbamates; Darunavir; Fluorescence; Fluorescent Dyes; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Pyridines; Pyrones; Sulfonamides | 2015 |
Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugates--proof of concept for HIV mucosal pre-exposure prophylaxis.
Topics: Administration, Rectal; Animals; Caco-2 Cells; Carbamates; Cell-Penetrating Peptides; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Intestinal Mucosa; Male; Mice; Mice, Inbred Strains; Nanoconjugates; Peptides, Cyclic; Polyethylene Glycols; Pre-Exposure Prophylaxis; Sulfonamides | 2016 |
Same patient, new stone composition: amprenavir urinary stone.
Topics: Adult; Anti-HIV Agents; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides; Tomography, X-Ray Computed; Urinary Calculi | 2008 |
HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.
Topics: Animals; Apoptosis; Carbamates; Cell Line; Cell Membrane Permeability; Endoplasmic Reticulum; Furans; HIV Infections; HIV Protease Inhibitors; Intestinal Mucosa; Lopinavir; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Pyrimidinones; Ritonavir; Stress, Physiological; Sulfonamides; Transcription Factor CHOP | 2010 |
Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
Topics: Atazanavir Sulfate; Carbamates; Cell Line; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Phenotype; Pyridines; Recombination, Genetic; Sulfonamides; Treatment Failure | 2010 |
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
Topics: Adult; Anti-HIV Agents; Carbamates; Case-Control Studies; Cohort Studies; Confidence Intervals; Dideoxynucleosides; Female; France; Furans; HIV Infections; Hospitals, Isolation; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Organophosphates; Regression Analysis; Risk; Ritonavir; Sulfonamides | 2010 |
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
Topics: Carbamates; Crystallography, X-Ray; Darunavir; Dimerization; Drug Design; Drug Resistance, Multiple, Viral; Furans; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Proteins; Structure-Activity Relationship; Sulfonamides | 2010 |
Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study.
Topics: Adolescent; Body Mass Index; Carbamates; CD4 Lymphocyte Count; Child; Cohort Studies; Cross-Sectional Studies; Female; Furans; Glucose Intolerance; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Insulin Resistance; Male; Obesity; Prevalence; Prospective Studies; Puberty; Sulfonamides; United States | 2011 |
Therapeutic amprenavir concentrations in cerebrospinal fluid.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4-Positive T-Lymphocytes; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Middle Aged; Sulfonamides; Tandem Mass Spectrometry | 2012 |
Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir.
Topics: Amino Acids; Carbamates; Catalytic Domain; Computer Simulation; Drug Resistance; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Mutation; Protein Binding; Sulfonamides; Thermodynamics | 2012 |
Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carbamates; Drug Administration Schedule; Female; Furans; Glucose; HIV Infections; Humans; Lipid Metabolism; Male; Pilot Projects; Prospective Studies; Sulfonamides | 2002 |
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor ab
Topics: Carbamates; Cell Line; Coculture Techniques; Drug Resistance, Viral; Furans; Gene Products, gag; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nelfinavir; Protein Precursors; Sulfonamides; Virus Replication | 2002 |
Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.
Topics: Adult; Anti-HIV Agents; Carbamates; Chemistry, Pharmaceutical; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Organophosphates; Prodrugs; Ritonavir; Semen; Sulfonamides | 2002 |
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir; Zalcitabine | 2002 |
Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Topics: Carbamates; Cross-Sectional Studies; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Retrospective Studies; RNA, Viral; Sulfonamides; Viremia | 2002 |
Using Agenerase. Nutritional considerations affect bioavailability of new P.I.
Topics: Biological Availability; Carbamates; Dietary Fats; Food-Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; Vitamin E | 1999 |
Agenerase approved by FDA.
Topics: Carbamates; Drug Administration Schedule; Drug Approval; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration | 1999 |
Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.
Topics: Algorithms; Carbamates; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Phenotype; Pyrimidinones; Sulfonamides | 2003 |
Genotype-phenotype discordance: the evolution in our understanding HIV-1 drug resistance.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Phenotype; Pyrimidinones; Sulfonamides | 2003 |
Amprenavir (AGENERASE) oral solution: warning for some patients.
Topics: Administration, Oral; Carbamates; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Solutions; Sulfonamides | 2000 |
Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection.
Topics: Acidosis, Lactic; Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Carbamates; Diagnosis, Differential; Didanosine; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Female; Furans; Guillain-Barre Syndrome; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Organophosphonates; Organophosphorus Compounds; Risk Assessment; Severity of Illness Index; Stavudine; Sulfonamides; Tenofovir | 2003 |
Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome | 2003 |
Potent antiviral activity of amprenavir in primary macrophages infected by human immunodeficiency virus.
Topics: Carbamates; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Macrophages; Sulfonamides; Virus Replication | 2004 |
Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.
Topics: Carbamates; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyridines; Pyrimidinones; Pyrones; RNA, Viral; Sulfonamides | 2004 |
HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
Topics: Amino Acid Substitution; Carbamates; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Microbial Sensitivity Tests; Mutation; Mutation, Missense; Phenotype; Retrospective Studies; Salvage Therapy; Sulfonamides; Viral Load | 2004 |
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.
Topics: Adult; Anti-Retroviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Mutation; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides | 2004 |
Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children.
Topics: Adolescent; Anti-HIV Agents; Area Under Curve; Carbamates; Child; Delavirdine; Drug Combinations; Furans; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Sulfonamides | 2004 |
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Male; Middle Aged; Mutation, Missense; Ritonavir; Selection, Genetic; Sulfonamides; Treatment Failure; Viral Load; Viremia | 2004 |
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretro
Topics: Amino Acid Substitution; Carbamates; Cohort Studies; Drug Resistance, Multiple, Viral; Furans; Genes, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Multivariate Analysis; Mutation; Phenotype; Pyrimidinones; Regression Analysis; Sulfonamides | 2004 |
Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.
Topics: Adult; Amniotic Fluid; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Maternal-Fetal Exchange; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Saquinavir; Sulfonamides | 2004 |
Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Directly Observed Therapy; Drug Administration Schedule; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Pilot Projects; Ritonavir; Statistics, Nonparametric; Sulfonamides; Treatment Outcome; Viral Load | 2004 |
Virtual screening of HIV-1 protease inhibitors against human cytomegalovirus protease using docking and molecular dynamics.
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Binding Sites; Carbamates; Crystallography, X-Ray; Cytomegalovirus; Cytomegalovirus Infections; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Structure; Peptide Hydrolases; Sulfonamides | 2005 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides | 2005 |
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.
Topics: Carbamates; Chronic Disease; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Nelfinavir; Retrospective Studies; Sulfonamides; Virus Replication; Withholding Treatment | 2005 |
Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.
Topics: Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Multiple, Viral; Follow-Up Studies; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Treatment Failure; Viral Load | 2005 |
A long-term survival case of small cell lung cancer in an HIV-infected patient.
Topics: Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Benzoxazines; Camptothecin; Carbamates; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Administration Schedule; Furans; HIV Infections; HIV Long-Term Survivors; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxazines; Ritonavir; Sulfonamides; Tomography, X-Ray Computed | 2005 |
Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.
Topics: Adult; Atazanavir Sulfate; Carbamates; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Saquinavir; Sulfonamides | 2005 |
Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations.
Topics: Adult; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mutation; Organophosphates; Prodrugs; Sulfonamides | 2006 |
Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Drug Administration Schedule; Drug Interactions; Furans; HIV Infections; Humans; Oligopeptides; Organophosphates; Pyridines; Sulfonamides; Treatment Failure; Viremia | 2006 |
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
Topics: Carbamates; Codon; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Nelfinavir; Phenotype; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2006 |
Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus.
Topics: Adult; Carbamates; Desensitization, Immunologic; Drug Hypersensitivity; Exanthema; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 2006 |
Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.
Topics: Adult; Anti-HIV Agents; Carbamates; Furans; Hepatitis C; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Metabolic Clearance Rate; Middle Aged; Organophosphates; Sulfonamides; Treatment Outcome | 2006 |
A combined empirical and mechanistic codon model.
Topics: Amino Acid Substitution; Animals; Anti-HIV Agents; Carbamates; Chloroplasts; Codon; Drug Resistance, Viral; Evolution, Molecular; Furans; Genes, Mitochondrial; Genes, Viral; HIV Infections; HIV Protease; HIV-1; Humans; Markov Chains; Models, Genetic; Models, Statistical; Mutation; Selection, Genetic; Sulfonamides | 2007 |
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
Topics: Carbamates; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Sulfonamides; Treatment Failure; Viral Load | 2007 |
Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
Topics: Adenine; Adult; Age Factors; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; Carbamates; Creatinine; Didanosine; Drug Interactions; Female; Furans; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Linear Models; Male; Middle Aged; Organophosphonates; Sulfonamides; Tenofovir; Time Factors | 2007 |
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Attention; Bilirubin; Carbamates; Chromatography, High Pressure Liquid; Female; Furans; HIV Infections; Humans; Liver Diseases; Male; Middle Aged; Organophosphates; Plasma; Ritonavir; Sulfonamides; Time Factors | 2007 |
Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels.
Topics: Adult; Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Furans; Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Middle Aged; Ritonavir; Sulfonamides; Treatment Outcome | 2007 |
Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
Topics: Carbamates; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome | 2008 |
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; France; Furans; HIV Infections; Humans; Male; Models, Biological; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2008 |
[Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides | 2008 |
Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.
Topics: Antiviral Agents; Blood Proteins; Carbamates; Clinical Trials as Topic; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Orosomucoid; Protein Binding; Sulfonamides | 1996 |
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy.
Topics: Adult; Aged; Anti-HIV Agents; Carbamates; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Division; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ki-67 Antigen; Lymph Nodes; Male; Middle Aged; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.
Topics: Amino Acid Substitution; Carbamates; Clinical Trials as Topic; Databases, Factual; DNA, Viral; Furans; Genetic Linkage; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Methionine; Nelfinavir; Phenotype; Polymerase Chain Reaction; Ritonavir; Saquinavir; Sulfonamides; Valine | 1998 |
Phase III results of second-generation HIV protease inhibitor reported.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine | 1998 |
The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir.
Topics: Carbamates; Dideoxynucleosides; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Maternal-Fetal Exchange; Placenta; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
Updated data on amprenavir.
Topics: Adult; Carbamates; Child; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Semen; Sulfonamides; Viral Load | 1999 |
Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Saquinavir; Sulfonamides; Zidovudine | 1999 |
Amprenavir approved for HIV treatment.
Topics: Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration | 1999 |
Amprenavir: a new HIV protease inhibitor.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Clinical Trials as Topic; Cross Reactions; Diarrhea; Drug Administration Schedule; Drug Interactions; Drug Resistance, Microbial; Exanthema; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Nausea; Stevens-Johnson Syndrome; Sulfonamides | 1999 |
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Dideoxynucleosides; Furans; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lymph Nodes; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Sulfonamides; Time Factors; Viral Load; Viremia; Zidovudine | 2000 |
Amprenavir study results released.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load; Zidovudine | 1999 |
A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.
Topics: Anti-HIV Agents; Carbamates; Drug Hypersensitivity; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutagenesis, Site-Directed; Sulfonamides | 2000 |
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.
Topics: Alkynes; Benzoxazines; Calibration; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2000 |
[Second chance therapy. New protease inhibitor for salvage therapy].
Topics: Carbamates; Drug Therapy, Combination; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Salvage Therapy; Sulfonamides; Treatment Outcome | 2000 |
Amprenavir approved.
Topics: Anti-HIV Agents; Carbamates; Controlled Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Female; Follow-Up Studies; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Sulfonamides; Treatment Outcome; United States; United States Food and Drug Administration | 1999 |
Mutation causes sensitivity.
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Sulfonamides | 2000 |
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.
Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Furans; HIV Antibodies; HIV Core Protein p24; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Lamivudine; Neutralization Tests; Ritonavir; Sulfonamides; Zidovudine | 2000 |
Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Child; Child, Preschool; Cyclopropanes; Delavirdine; Drug Interactions; Drug Therapy, Combination; Furans; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; Time Factors | 2000 |
Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Drug Therapy, Combination; Furans; HIV Infections; Humans; Oxazines; Oxidoreductases, N-Demethylating; Ritonavir; Sulfonamides | 2000 |
Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.
Topics: Carbamates; Drug Resistance, Microbial; Drug Resistance, Multiple; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Raising levels of amprenavi.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Viral Load | 2000 |
Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dideoxynucleosides; Epstein-Barr Virus Infections; Flow Cytometry; Furans; Genotype; HIV Infections; HIV-1; Humans; Immunoglobulin M; Lamivudine; Longitudinal Studies; Male; Proto-Oncogene Proteins c-bcl-2; Receptors, CCR5; Sulfonamides; Time Factors; Zidovudine | 2001 |
Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV.
Topics: Adult; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Sulfonamides | 2001 |
Liquid chromatographic-tandem mass spectrometric determination of amprenavir (agenerase) in serum/plasma of human immunodeficiency virus type-1 infected patients receiving combination antiretroviral therapy.
Topics: Anti-HIV Agents; Carbamates; Chromatography, Liquid; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mass Spectrometry; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides | 2001 |
Double protease inhibitor regimens with amprenavir show promise.
Topics: Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Saquinavir; Sulfonamides; Viral Load; Zidovudine | 1998 |
Amprenavir made available through early access program.
Topics: Anti-HIV Agents; Carbamates; Drug Approval; Furans; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States | 1998 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine | 1995 |
Conference looks at HIV drug resistance.
Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine; Viremia; Zalcitabine; Zidovudine | 1995 |
ICAAC update.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Viral Load | 1996 |
Pediatric trial of 141W94, Vertex protease inhibitor.
Topics: Adolescent; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Clinical Trials, Phase III as Topic; Furans; HIV Infections; Humans; Infant; Patient Selection; Sulfonamides; United States; Viral Load | 1997 |
141 (Vertex-478).
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine | 1997 |
Protease inhibitor failure trial: combination 1592, 141W94, and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials, Phase II as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Multicenter Studies as Topic; Oxazines; Patient Selection; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure | 1997 |
What's new and what's next.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-2; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
Selected highlights from the 5th Conference on Retroviruses and Opportunistic Infections.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Carbamates; Chicago; Clinical Trials as Topic; Congresses as Topic; Cyclopropanes; Dideoxynucleosides; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
New drugs: amprenavir and abacavir.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine | 1998 |
What's new, what's next?
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Carbamates; Decision Making; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Patient Compliance; Saquinavir; Sulfonamides | 1998 |
New drugs on the horizon.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; United States; Zidovudine | 1998 |
New drugs in development.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Imidazoles; Kidney Diseases; Lopinavir; Oxazines; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 1998 |
Amprenavir (Agenerase) now available in expanded access.
Topics: Adolescent; Adult; Carbamates; Child; Child, Preschool; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 1998 |
Access to efavirenz and amprenavir.
Topics: Alkynes; Benzoxazines; Carbamates; Cyclopropanes; Furans; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; United States | 1998 |
Expanded access program begins.
Topics: Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Patient Selection; Sulfonamides; United States | 1998 |
Glaxo Wellcome's two new drugs.
Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 1998 |
What's new, what's next?
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 1999 |
Retrovirus conference report: three new agents to the rescue.
Topics: Anti-HIV Agents; Carbamates; Congresses as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Peptide Fragments; Pyrimidinones; Salvage Therapy; Sulfonamides; Viral Load; Virus Replication | 1999 |
Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference.
Topics: Adenine; Antiviral Agents; Bacterial Vaccines; Carbamates; Congresses as Topic; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Pneumococcal Infections; Sulfonamides; Vaccination; Viral Load | 1998 |
The new drugs and how to use them.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Sulfonamides | 1999 |
Some existing drugs work on resistant HIV.
Topics: Anti-HIV Agents; Carbamates; Dioxolanes; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Purine Nucleosides; Pyridines; Pyrones; Sulfonamides | 2000 |
Study: new drug doesn't display cross-resistance.
Topics: Carbamates; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Salvage Therapy; Sulfonamides | 1999 |
Amprenavir, new protease inhibitor, approved.
Topics: Adolescent; Adult; Carbamates; Child; Child, Preschool; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States Food and Drug Administration | 1999 |
Expanded access.
Topics: Adenine; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 1998 |
Antivirals update.
Topics: Anti-HIV Agents; Carbamates; Delavirdine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nevirapine; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides | 1998 |
Drug approval.
Topics: Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration | 1999 |
Amprenavir (Agenerase) receives FDA approval. Food and Drug Administration.
Topics: Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration | 1999 |
Amprenavir (Agenerase).
Topics: Biological Availability; Carbamates; Clinical Trials as Topic; Diet; Drug Interactions; Drug Resistance, Microbial; Drug Storage; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Pharmacokinetics; Sulfonamides | 1999 |
Expanded access.
Topics: Adenine; Anti-HIV Agents; Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; United States; United States Food and Drug Administration | 1999 |
Amprenavir approved.
Topics: Anti-HIV Agents; Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration | 1999 |
New treatment options.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 1999 |
Antiretroviral update from the Interscience Conference on Antimicrobial Agents and Chemotherapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
New expanded access drugs for use in combination therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Child; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Pregnancy; Sulfonamides | 1998 |
Amprenavir: a new protease inhibitor nears approval.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sulfonamides | 1999 |
New anti-HIV drugs in development.
Topics: Adverse Drug Reaction Reporting Systems; Anti-HIV Agents; Capsules; Carbamates; Chemistry, Pharmaceutical; Didanosine; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Menorrhagia; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 1999 |
Novel approaches for the treatment of HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; Genetic Therapy; Heterocyclic Compounds; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Oxazines; Receptors, Chemokine; Reverse Transcriptase Inhibitors; Sulfonamides; Zinc Fingers | 1998 |
Fifth Conference on Retroviruses & Opportunistic Infections. Interview by Ron Baker.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Congresses as Topic; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Furans; Genetic Techniques; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 1998 |
[Determining resistance in HIV therapy. Careful interpretation only].
Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Resistance, Microbial; Furans; HIV; HIV Infections; Humans; Mutation; Sulfonamides | 2001 |
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reference Standards; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides | 2001 |
Drifting agenda for federal treatment research.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, Combination; Financing, Government; Furans; HIV Infections; HIV Protease Inhibitors; National Institutes of Health (U.S.); Reverse Transcriptase Inhibitors; Sulfonamides; United States | 2001 |
Amping amprenavir with ritonavir.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides; Viral Load | 2001 |
Resistant to everything.
Topics: Aged; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; Humans; Lopinavir; Male; Patient Compliance; Pyrimidinones; Ritonavir; Stavudine; Sulfonamides; Viral Load | 2001 |
Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 2001 |
Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Microbial; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation; Sulfonamides; Viral Load | 2001 |
Amprenavir (Agenerase).
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Practice Guidelines as Topic; Sulfonamides | 2000 |
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Drug Therapy, Combination; Furans; HIV; HIV Infections; Humans; Ritonavir; RNA, Viral; Sulfonamides | 2002 |
Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir?
Topics: Carbamates; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pilot Projects; Pyrimidinones; Ritonavir; Sulfonamides | 2002 |
Central nervous system toxicity and amprenavir oral solution.
Topics: Carbamates; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Sulfonamides | 2002 |
[Advances in the domain of HIV].
Topics: Anti-HIV Agents; Blood; Carbamates; Cerebrospinal Fluid; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genitalia; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Mutation; Phenotype; Randomized Controlled Trials as Topic; Retrospective Studies; Ritonavir; Sulfonamides; Time Factors; Viral Load | 2002 |
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
Topics: Adult; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Biomarkers; Carbamates; CD48 Antigen; CD8-Positive T-Lymphocytes; Dideoxynucleosides; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymphocyte Count; Male; Middle Aged; Reverse Transcriptase Inhibitors; Sulfonamides; T-Lymphocyte Subsets; Treatment Outcome; Viral Load; Viremia; Zidovudine | 2002 |
Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.
Topics: Carbamates; Dose-Response Relationship, Drug; Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides | 2002 |
Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Delavirdine; Drug Synergism; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2002 |
FDA approves new dosing for amprenavir and ritonavir combination.
Topics: Carbamates; Drug Approval; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides; United States; United States Food and Drug Administration | 2002 |
New dosing regimen approved.
Topics: Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides | 2002 |
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Infections; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Lipodystrophy update.
Topics: Carbamates; Furans; Growth Hormone; HIV Infections; Humans; Lipodystrophy; Reverse Transcriptase Inhibitors; Sulfonamides; Surgery, Plastic | 2002 |